Incidence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli isolated from women with urinary tract infections in Jordan

约旦女性尿路感染患者中分离出的产超广谱β-内酰胺酶(ESBL)大肠杆菌的发生率

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Urinary tract infections are one of the world's major health problems. In addition, clinical disorders may result from the presence of bacteria or fungi in urine. The aim of this study was to isolate Escherichia coli (E. coli) strains from midstream urine samples, and to determine molecular characterization of encoded Extended Spectrum Beta-Lactamase (ESBL) genes. MATERIALS AND METHODS: Collected urine samples were streaked on MacConkey, blood and EMB agar plates, then identifying E. coli isolates by using antibiotic susceptibility tests. ESBL production was measured using double disc diffusion. Furthermore, uniplex PCR was performed to identify two ESBL genes (bla (CTX) and bla (TEM)). RESULTS: Among 412 isolates, 198 (48.1%) were E. coli strains, followed by Staphylococcus saprophyticus, Klebsiella sp., Serratia sp., Enterococci sp. and Proteus sp. with frequency of 132 (32.0%), 51 (12.4%), 15 (3.6%), 10 (2.4%), and 6 (1.5%) respectively. Female participants who were between the ages of 40 and 49 years old, married, and pregnant were more likely to develop urinary tract infections (UTIs). E. coli species were present in 189 (95.5) of the recurrent UTIs. Regarding antimicrobial susceptibility testing of E. coli isolates, the highest percentage of resistance and susceptible rates were found for nalidixic acid (75.8%) and gentamicin (64.1%) respectively. Among the E. coli isolates, 25 (12.6%) were ESBL-producers. The bla (CTX-M) gene was genetically confirmed in 20 (10.1%) of the isolates. CONCLUSION: E. coli is the most common cause of UTI and ESBL production leads to increased resistance to common antibiotics and complicates treatment strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。